macro

Craig-Hallum Initiates Quoin Pharmaceuticals at Buy Rating

Craig-Hallum analysts have started coverage of Quoin Pharmaceuticals shares with a Buy rating, according to Dow Jones Newswires.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Dow Jones Newswires reports that analysts at Craig-Hallum have begun coverage of Quoin Pharmaceuticals (QNRX) and assigned the shares a Buy rating.

The report does not include the reasoning behind the rating or a price target. It only links to the Benzinga ratings page for the stock.

why it matters

Initial coverage from smaller brokerage firms on little-known biotech issuers usually affects the stock in question rather than the broader market. The analyst's full report would be needed to understand the valuation logic.

tags

instruments

QNRX

sources

  1. Quoin Pharmaceuticals Initiated at Buy by Craig-Hallum — Dow Jones Newswires, 20 November 2026 at 18:03 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗